Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Eisai’s Antiepileptic Med Fycompa Scores Label Expansions in China
August 4, 2021
- Shionogi Sees Sales Dip in Q1 despite Japan Growth; Crestor Royalty Nearly Zero
August 3, 2021
- Chugai Launches Blood-Based Comprehensive Genomic Profiling Test for Solid Tumors
August 3, 2021
- AstraZeneca to Start e-Labeling, Will Complete Process for All Products by 2022-End
August 3, 2021
- Viatris Takes Over Celecox, Lipitor MAs in Japan
August 3, 2021
- MSD Renews Warning for Fainting after Gardasil Vaccination
August 3, 2021
- Takeda to Challenge Irish Authorities’ Break Fee Tax Assessment
August 3, 2021
- Kowa Recalls All Lots of Livalo OD Tablets 1 mg over Purity Test Results
August 3, 2021
- Astellas Hooks Up with Israeli Firm for Mitochondrial Cell Therapy Programs
August 3, 2021
- Ono Chief, Honjo to Face Off in Opdivo Royalty Feud on September 2
August 3, 2021
- Daiichi Sankyo’s Q1 Sales Surge on Upbeat Global Brands
August 2, 2021
- Astellas Logs Sales Growth in Q1, but Profits Drop Sharply on Write-Offs
August 2, 2021
- Takeda’s Q1 Sales Rise on Diabetes Divestiture; Plant Re-Inspection Results Expected Late October
August 2, 2021
- PeptiDream, Alnylam Collaborate to Discover and Develop Peptide-siRNA Conjugates
August 2, 2021
- Biogen, Eisai Reveal Real-World Study Design of Aducanumab
August 2, 2021
- Ono’s Q1 Sales Up 16.6% on Opdivo Indication Expansions
August 2, 2021
- Nicholas Jones Named New Biogen Japan President
August 2, 2021
- Takeda, American VC Forge New Company to Develop Norovirus Vaccine
August 2, 2021
- Sumitomo Dainippon’s Q1 Sales Skid 2.0% on Lower Latuda Revenue
July 30, 2021
- Takeda’s Narcolepsy Drug Snags FDA’s Breakthrough Therapy Tag
July 30, 2021
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…